Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    114580
Show Display Options
Rank Status Study
1 Completed Evaluation of the Bioequivalence of a Combined Formulated Tablet
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg;   Drug: Dolutegravir 50 mg;   Drug: abacavir 600 mg/lamivudine 300 mg

Indicates status has not been verified in more than two years